Frequently asked questions

Answers about the 2027 GLP-1 exclusion, what members can do, and how One Body works.

General information, not medical, legal or tax advice. Talk with your prescriber before changing any medication, and check your own plan through Quantum Health or Express Scripts.

About the change

What exactly is changing?

From January 1, 2027, the Medical Trust will not cover GLP-1 medications prescribed for weight loss, “with or without comorbidities.” Wegovy and Zepbound go on the Medical Trust’s Drug Exclusion List. No prior authorization or medical-necessity requests will be approved. Spending on excluded drugs doesn’t count toward your deductible or out-of-pocket maximum. The EncircleRx program and its Omada requirement end on December 31, 2026. (The facts on one page)

Is diabetes treatment still covered?

Yes. GLP-1 medications “will continue to be covered for type 2 diabetes treatment, subject to applicable prior authorization and utilization management requirements.” CPG has also said prediabetes is not covered.

What about Wegovy for heart disease, or Zepbound for sleep apnea?

Those uses lose coverage too. The FDA has approved Wegovy to reduce the risk of heart attack and stroke in adults with established heart disease, and to treat MASH (a serious liver disease). It has approved Zepbound for moderate-to-severe obstructive sleep apnea. But the letter members received puts the products themselves on the Drug Exclusion List, and says coverage continues only for type 2 diabetes. We are asking the Medical Trust to keep these uses covered through prior authorization (our asks).

If this applies to you, plan with your prescriber for coverage ending on January 1. To check your own prescription, call Quantum Health, which guides members of the Medical Trust’s Anthem and Cigna plans, at 866-871-0629 (weekdays, 8:30 AM to 10 PM Eastern), and ask for the answer by email or letter. There is more on getting answers in writing in Help if you’re losing coverage.

Does this affect retirees, Kaiser members or Hawaii plans?

  • Early retirees (under 65): yes. The change is listed for “active employees and early retirees.”
  • Retirees on Medicare: it does not appear to apply. CPG’s Annual Enrollment page lists the change only for active employees and early retirees, and Medicare retirees’ drug coverage appears to follow Medicare drug-plan rules instead. To be sure, call the member-services number on your UnitedHealthcare card and ask: “Will my plan cover Wegovy or Zepbound in 2027, and for which uses?”
  • Kaiser and Hawaii (HMSA) members: the documents we found don’t say clearly. Please ask your plan.

Can I appeal?

You can always file an internal appeal; your plan document handbook explains how (CPG health plan documents). But the plan documents limit independent external review to denials “involving medical judgment” (for prescriptions, also “a decision based on medical information”), and a denial based purely on an exclusion usually doesn’t qualify. A dispute about a use other than weight loss (heart risk, sleep apnea, liver disease) might be different. This is general information, not legal advice.

Why is the Medical Trust doing this?

Cost. Without changes, 2027 rates would have risen 22.5%. Ending this coverage saves $8.9 million, or 3.6 percentage points of that increase. CPG called it “unwelcome news,” and said “it wasn’t an easy decision to make.” There are ways to save money that don’t cut people off mid-treatment. (What we are asking for)

Won’t keeping coverage raise premiums for struggling parishes?

Yes, full coverage costs money. So each of our requests is narrow, and each costs less than full coverage:

  • a short transition for people already in treatment;
  • the heart, sleep apnea and liver uses the FDA has approved;
  • a middle path for 2028, such as a member-paid copay tier or a plan contribution toward cheaper direct purchases.

CPG itself says members can buy these medicines directly from the manufacturers for about half of what the plan pays for them (the facts). So a plan contribution toward direct purchases could keep people in treatment for much less than full coverage. Dioceses can also help small parishes with the higher 2027 premiums, and we support that.

If you are taking one of these medications

What should I do before January 1?

  1. Talk with your prescriber now about a plan for 2027, so you don’t face a gap. The Wegovy label says that if 2 or more doses in a row are missed, dose escalation should restart at a lower dose.
  2. Ask your employer whether you can still sign up for a 2027 health flexible spending account; employers set their own deadlines. Medical Trust plan choices for 2027 are fixed once annual enrollment closes in November, unless you have a qualifying life event such as marriage or the birth of a child.
  3. Ask whether a final fill makes sense while you’re still covered. Check your price in the Express Scripts app or at express-scripts.com first. Plans usually limit how much you can get at once and how soon you can refill.
  4. Get answers in writing from Quantum Health (866-871-0629) about what is and isn’t covered.
  5. If you and your prescriber decide to stop, ask about stepping the dose down rather than stopping all at once. Many doctors do this, though no official schedule exists yet. Never change your dose without your prescriber.

What will it cost to buy directly?

Manufacturer prices as of October 2026 (they can change):

Product Self-pay price
Wegovy pens $349 per 28-day box at doses up to 2.4 mg ($399 for Wegovy HD 7.2 mg)
Wegovy pill $149, $199 or $299 a month by dose
Zepbound $299–$449 a month by dose, if refilled on time

Novo Nordisk’s Wegovy savings card lowers your copay only while your insurance covers Wegovy, so that discount ends on January 1. After that, the same card gets you the self-pay prices above, or you can order from NovoCare Pharmacy. Lilly’s Zepbound card has a version for plans that don’t cover Zepbound, but it charges about the same prices and expires December 31, 2026; Lilly hasn’t published 2027 terms yet. Neither company’s patient-assistance program lists these medicines, and both exclude people with commercial insurance. See Help if you’re losing coverage for where to buy.

Can I use an HSA or FSA?

Generally yes, when the medication is prescribed to treat a diagnosed disease such as obesity (IRS Publication 502). CPG confirmed in August that this “is still qualified as an expense.” NovoCare Pharmacy and LillyDirect both say they accept HSA and FSA cards. But the self-pay savings terms for Wegovy at other pharmacies and for the Zepbound KwikPen say you won’t seek reimbursement from a health care reimbursement account. If you plan to buy that way, ask your account administrator first, and keep your receipts.

What about compounded semaglutide or tirzepatide?

The FDA ended the shortage-era flexibility for compounded copies in 2025. It has warned many telehealth sellers and recorded hundreds of adverse-event reports. If you consider it, talk with your prescriber, and use only state-licensed pharmacies. We don’t recommend any compounded product.

About One Body

Is the letter giving up on coverage for weight loss?

No. Obesity is a chronic disease, and treating it is good stewardship of the body. For everyone taking these medicines, including for weight loss, the letter asks for:

  • six to twelve months to transition, so no one has to stop all at once on January 1;
  • coverage brought back for 2028 through a middle path, such as a member copay tier, clinical criteria with a lifestyle program, one preferred medicine at a negotiated price, or a plan contribution toward cheaper direct purchases.

It also asks that the heart, sleep apnea and liver uses the FDA has approved stay covered. We start with these requests because each costs the plan much less than full coverage, which makes them easier to agree to before January 1. (What we are asking for)

Who is behind this?

Episcopal clergy, lay employees and family members who are Medical Trust members. We are independent: not affiliated with or endorsed by the Church Pension Group, the Medical Trust or The Episcopal Church. (About One Body)

Do you take money from drug companies?

No. We take no money from pharmaceutical companies or groups they fund. The site is paid for by its organizers.

Do I have to be affected to sign?

No. Spouses and family members, clergy colleagues, lay employees, vestries, bishops, deputies, clinicians and any Episcopalian who cares about this are welcome. You choose whether your name is shown.

What happens to my information?

We collect as little as we can. We never ask for member IDs, diagnoses or medication doses. Stories are used only at the level you choose, and unless you choose to be named, only the campaign organizers know who sent a story. You can withdraw consent or ask us to delete your information at any time. Our privacy policy shows who sees what, and the Consumer Health Data Privacy Policy covers stories and the survey.

Is this against the Church Pension Group?

No. CPG serves the whole Church, and its people are working under real pressure. We want to work with the Medical Trust, and we will publish its answers accurately and say thank you where it moves.

Last updated

Back to top